US Food and Drug Administration

Company

Last mentioned: Mar 10, 2026

Timeline

  1. Potential Approval

    Estimated approval date based on 6-month priority review timeline.

  2. FDA Filing Deadline

    Target date for completing the BLA application for accelerated approval.

  3. Phase 3 Success

    Vertex announces povetacicept met primary endpoint in IgA nephropathy trial.

  4. Alpine Acquisition

    Vertex acquires Alpine Immune Sciences for $4.9B to obtain povetacicept.

Stories mentioning US Food and Drug Administration 1

clinical-trial Bullish

Vertex Kidney Drug Success Signals Major Pivot Beyond Cystic Fibrosis

Vertex Pharmaceuticals reported that its Phase 3 trial for povetacicept met its primary endpoint, showing a 52% reduction in proteinuria for patients with IgA nephropathy. The company plans to file for FDA accelerated approval by the end of March 2026, utilizing a priority review voucher to expedite the process.

2 sources